Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Prevalence and Management of Panic Attacks during Infliximab Infusion in Psoriatic Patients

Saraceno R.a · Faleri S.a · Ruzzetti M.a · Centonze D.b · Chimenti S.a

Author affiliations

Departments of aDermatology and bNeuroscience, University of Rome Tor Vergata, Rome, Italy

Related Articles for ""

Dermatology 2012;225:236–241

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 21, 2012
Accepted: September 18, 2012
Published online: November 22, 2012
Issue release date: January 2013

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Psoriasis is a chronic, inflammatory skin disease associated with anxiety and depression. Infliximab (IFX) is a human/mouse chimeric anti-TNF-α antibody effective in the treatment of psoriasis. Objective: The aim of this study was to evaluate the prevalence of panic disorders in psoriatic patients during IFX infusions. Methods: A retrospective study was performed on patients affected with psoriasis who were treated with IFX from 2002 to 2011 at a single center. Panic disorders were defined using the clinical criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. A population of dermatological patients under treatment with IVG, rituximab, apheresis, intravenous corticosteroids and antibiotics was considered as the control group. Results: A total of 141 patients were evaluated. Of these, 6 (4.25%) experienced panic attacks during the infusion; 16 (11.3%) had a medical history of panic attack and of those 5/16 (31%) experienced panic attacks during IFX infusion. In the control group panic attacks were not recorded. Conclusion: We describe 6 cases of patients in whom panic attacks were triggered by IFX infusion. Premedication with oral benzodiazepine and a slow rate of infusion is recommended.

© 2012 S. Karger AG, Basel


References

  1. Saraceno R, Saggini A, Pietroleonardo L, Chimenti S: Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27–37.
  2. Scallon BJ, Moore MA, Trinh H, et al: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251–259.
  3. Chaudhari U, Romano P, Mulcahy LD, et al: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357:1842–1847.
  4. Gottlieb AB, Chaudari U, Mulcahy LD, et al: Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829–835.
  5. Reich K, Nestle FO, Papp K, et al: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.
  6. Kalb RE, Gurske J: Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005;53:616–622.
  7. Smith CH, Jackson K, Bashir SJ: Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006;155:160–169.
  8. Langley RG, Gupta AK, Cherman AM, Inniss KA: Biologic therapeutics in the treatment of psoriasis. Part 1: review. J Cutan Med Surg 2007;11:99–122.
  9. Tompkins O: Panic attacks. AAOHN J 2010;58:268.
  10. Tarlo SM, Poonai N, Binkley K, Antony MM, Swinson RP: Responses to panic induction procedures in subjects with multiple chemical sensitivity/idiopathic environmental intolerance: understanding the relationship with panic disorder. Environ Health Perspect 2002;4:669–671.
    External Resources
  11. Han C, Lofland JH, Zhao N, Schenkel B: Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011;10:843–850.
    External Resources
  12. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM: The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based color study. Arch Dermatol 2010;146:891–895.
  13. Esposito M, Saraceno R, Giunta A, et al: An Italian study on psoriasis and depression. Dermatology 2006;212:123–127.
  14. Han C, Lofland JH, Zhao N, Schenkel B: Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011;10:843–850.
    External Resources
  15. DSM-IV-TR. Manuale Diagnostico e Statistico dei Disturbi Mentali, text revision. ICD-10/ICD-9-CM. Milan, Masson, 2007.
  16. Vermeire S, Noman M, Van Assche G, et al: Autoimmunity associated with anti-tumor necrosis factor treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003;125:32–39.
  17. Eriksson C, Engstrand S, Sundqvist KG, et al: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha. Ann Rheum Dis 2005;64:403–407.
  18. Charles PJ, Smeenk RJ, De Jong J, et al: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo controlled trials. Arthritis Rheum 2000;43:2383–2390.
  19. http://www.merckmanuals.com/professional/lexicomp/infliximab.html.
  20. Roblin X, Oltean P, Heluwaert F, Bonaz B: Panic attack with suicide: an exceptional adverse effect of infliximab. Dig Dis Sci 2006;51:1056.
  21. Farrell RJ, Shah SA, Lodhavia PJ, et al: Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000;95:3490–3497.
  22. Eshuis EJ, Magnin KM, Stokkers PC, et al: Suicide attempt in ulcerative colitis patient after 4 months of infliximab therapy – a case report. J Crohns Colitis 2010;4:591–593.
  23. Noyes R Jr: Suicide and panic disorder: a review. J Affect Disord 1991;22:1–11.
  24. Yates WR: Phenomenology and epidemiology of panic disorder. Ann Clin Psychiatry 2009;21:95–102.
    External Resources
  25. Hestad KA, Tønseth S, Støen CD, et al: Inflammation and depression: further studies are needed. J ECT 2005;21:52.
  26. Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374–383.
  27. Ohno Y: New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorder. Cent Nerv Syst Agents Med Chem 2010;10:148–157.
  28. Schumacher J, Deckert J: Serotonin transporter polymorphism and panic disorders. Genome Med 2010;2:40.
  29. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE: The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006;63:415–424.
  30. Papoutsaki M, Talamonti M, Giunta A, et al: The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010;221(suppl 1):43–47.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 21, 2012
Accepted: September 18, 2012
Published online: November 22, 2012
Issue release date: January 2013

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.